Equities analysts forecast that Sensus Healthcare Inc (NASDAQ:SRTS) will post ($0.02) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Sensus Healthcare’s earnings. The lowest EPS estimate is ($0.04) and the highest is $0.00. Sensus Healthcare reported earnings per share of ($0.08) during the same quarter last year, which would indicate a positive year over year growth rate of 75%. The company is scheduled to announce its next earnings report after the market closes on Thursday, May 9th.
According to Zacks, analysts expect that Sensus Healthcare will report full-year earnings of $0.02 per share for the current fiscal year, with EPS estimates ranging from ($0.01) to $0.08. For the next fiscal year, analysts forecast that the company will post earnings of $0.19 per share, with EPS estimates ranging from $0.01 to $0.32. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Sensus Healthcare.
Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings data on Thursday, February 14th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.03. Sensus Healthcare had a negative return on equity of 10.86% and a negative net margin of 7.65%. The business had revenue of $8.08 million during the quarter, compared to analyst estimates of $7.33 million.
NASDAQ:SRTS traded up $0.02 during midday trading on Friday, reaching $6.20. 945 shares of the company traded hands, compared to its average volume of 45,640. Sensus Healthcare has a twelve month low of $5.31 and a twelve month high of $9.23. The firm has a market capitalization of $106.21 million, a P/E ratio of -44.29 and a beta of -0.53.
In other Sensus Healthcare news, EVP Richard Golin sold 5,943 shares of the business’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $7.56, for a total transaction of $44,929.08. Following the completion of the transaction, the executive vice president now owns 925,237 shares in the company, valued at approximately $6,994,791.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 7,203 shares of company stock valued at $54,379 in the last quarter. 41.10% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Sensus Healthcare by 48.2% in the 3rd quarter. Vanguard Group Inc. now owns 305,833 shares of the company’s stock worth $2,563,000 after buying an additional 99,444 shares in the last quarter. Vanguard Group Inc raised its stake in shares of Sensus Healthcare by 48.2% in the 3rd quarter. Vanguard Group Inc now owns 305,833 shares of the company’s stock worth $2,563,000 after buying an additional 99,444 shares in the last quarter. Garrison Bradford & Associates Inc. raised its stake in shares of Sensus Healthcare by 275.1% in the 1st quarter. Garrison Bradford & Associates Inc. now owns 108,400 shares of the company’s stock worth $761,000 after buying an additional 79,500 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Sensus Healthcare by 75.0% in the 3rd quarter. Renaissance Technologies LLC now owns 48,100 shares of the company’s stock worth $403,000 after buying an additional 20,612 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Sensus Healthcare by 222.5% during the fourth quarter. Geode Capital Management LLC now owns 45,034 shares of the company’s stock worth $333,000 after purchasing an additional 31,070 shares during the period. 6.56% of the stock is currently owned by institutional investors.
About Sensus Healthcare
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Further Reading: Moving Average Convergence Divergence (MACD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.